KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Cash from Investing Activities (2017 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Cash from Investing Activities for 16 consecutive years, with -$37.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities rose 29.76% year-over-year to -$37.2 million, compared with a TTM value of $436.3 million through Dec 2025, up 473.44%, and an annual FY2025 reading of $436.3 million, up 473.44% over the prior year.
  • Cash from Investing Activities was -$37.2 million for Q4 2025 at Alnylam Pharmaceuticals, down from $501.1 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $501.1 million in Q3 2025 and bottomed at -$413.4 million in Q4 2021.
  • Average Cash from Investing Activities over 5 years is -$6.0 million, with a median of -$33.7 million recorded in 2024.
  • The sharpest move saw Cash from Investing Activities plummeted 775.01% in 2021, then skyrocketed 1756.55% in 2025.
  • Year by year, Cash from Investing Activities stood at -$413.4 million in 2021, then surged by 66.16% to -$139.9 million in 2022, then tumbled by 72.01% to -$240.7 million in 2023, then soared by 78.01% to -$52.9 million in 2024, then grew by 29.76% to -$37.2 million in 2025.
  • Business Quant data shows Cash from Investing Activities for ALNY at -$37.2 million in Q4 2025, $501.1 million in Q3 2025, and -$141.4 million in Q2 2025.